ETNB (89bio Inc) רווח למניה בארבעת הרבעונים האחרונים

The success of 89bio, Inc. (ETNB) is based on the trial results of pegozafermin against MASH and FDA approval. The 12-month YoY earnings per share growth rate illustrates the link between capitalization and efficiency, where 53.70 captures the current state of the parameter. Stability is ensured by strict temperature control of drug shipments and high confidence in the management team preparing the final stages of testing.
ETNB (89bio, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

To identify fundamental sector leaders, GURU.Markets analysts utilize trailing twelve-month (TTM) earnings per share growth rates, which measure the dynamics of net income per share relative to the previous period. In the case of 89bio, Inc. (ETNB), the year-over-year change in EPS (TTM) reflects the development efficiency of the flagship drug excluding M&A transactions, signaling real progress in commercialization or an increase in operating expenses.